AGEN Stock Summary and Trading Ideas (Agenus | NASDAQ:AGEN)

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Agenus trades on the NASDAQ stock market under the symbol AGEN.

As of April 2, 2026, AGEN stock price declined to $3.33 with 477,016 million shares trading.

AGEN has a beta of 1.57, meaning it tends to be more sensitive to market movements. AGEN has a correlation of 0.08 to the broad based SPY ETF.

AGEN has a market cap of $127.87 million. This is considered a Micro Cap stock.

Last quarter Agenus reported $34 million in Revenue and -$.37 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.91.

In the last 3 years, AGEN traded as high as $42.60 and as low as $1.38.

The top ETF exchange traded funds that AGEN belongs to (by Net Assets): VTI, VXF, IWC.

AGEN has outperformed the market in the last year with a return of +108.1%, while the SPY ETF gained +18.2%. In the last 3 month period, AGEN beat the market returning +6.1%, while SPY returned -3.6%. However, in the most recent 2 weeks AGEN has underperformed the stock market by returning -11.4%, while SPY returned -0.6%.

AGEN support price is $3.24 and resistance is $3.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGEN shares will trade within this expected range on the day.